about
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesFrom randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue fraOverall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the EurMET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.[Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer].[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study.[Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration].Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach.Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.In which context is physician empathy associated with cancer patient quality of life?[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys].Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas.The multiple paths towards MET receptor addiction in cancer.Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy.[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].[Systemic treatment of brain metastases from lung cancer].[Pulmonary MALT lymphoma revealing AIDS].[MET exon 14 mutation, new target in lung sarcomatoid carcinoma].Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter.Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.P14.11 Determination of the EGFR mutations including T790M in the cerebrospinal fluid of patients with leptomeningeal metastasis from EGFR mutant non small cell lung cancer.[A difficult diagnosis]
P50
Q27853282-6E47369C-B52A-4994-9760-AEC8CDF6F68FQ28289431-F5BFEB1E-FA93-4953-BF21-D494AD4B4181Q30535897-4D0B4340-1FBB-4A1A-9D2E-A1CA97AEC262Q33591738-92322675-856C-490B-BB99-8E98FDFFFA80Q34997421-79026A6E-3B49-43A8-B5BB-31BAF30FEF28Q35022194-D29434D7-DE7B-4DE5-B4A4-807AB65A0E08Q37706900-70440C22-7E90-41A6-89D5-F0F8B4C2D73DQ38735120-340E3F41-CDED-42FF-A10E-52C1D3B85E81Q38846778-0890A7E8-6891-45FF-91BD-383D6471D9BEQ38993994-54734698-97D7-412C-9153-80FD43AFAF69Q39105350-4A0B9673-BA3F-4C9B-8A01-C5111A8A7990Q39191903-12CA49A2-1D6C-4A82-B70A-A2A93D4D1700Q40522831-3CD1FC7E-FE18-47E9-8DA8-F99EC030C325Q42776312-4B3FD684-E376-425A-9A40-18E69552559FQ43880436-0B350B02-222B-4DBA-A50C-9CDD958593CBQ44048101-16A2168D-AB1F-427E-B516-D7D3551C9E43Q44763677-DEA784DF-EC7D-42B6-84E2-B93689BAED40Q44963640-90480AE7-DE18-4E51-B682-D22D3BC27A28Q47236718-C6EC63F6-5653-445D-9A28-0D1CC3FF2420Q47737772-84042301-D3CF-4E9A-8801-F2074B749CB5Q48225182-65FCD613-5985-4DC3-83F9-9865FDAA3F22Q48491269-91AE91CE-6979-489F-9715-40523D9FE975Q49703405-28D50F27-4794-4A7B-A455-11E349614C7BQ49953686-99F9FA21-5357-42B6-B749-2FD6D53148F9Q50139936-4B870ADB-54B3-4804-9701-237CBD22D707Q50155176-FD687159-24B2-4E4D-A968-3A1BED2C4102Q50942333-33A77DDC-4BE6-4D7C-9876-B158CB2E22C8Q51184551-9349CF0D-161C-4E78-8463-2FAC7DEF7C62Q52316580-A88B54C2-00BD-40E7-B6C6-5EBBC8C59B0AQ52672764-38FB4C50-45E3-4D1B-8817-AF46B2969A62Q52931826-F3CAA66B-697A-447A-8A01-77DE7BF616B9Q53067518-CE195A28-BFE5-46D8-B355-1B2D44CB9563Q53525392-97057EB7-3BB9-4988-895B-2ECDAC4CBF08Q53624838-2C33BDC4-6AD7-490A-BB72-E07D39D02EBEQ54119025-F03B9DE5-72B3-48D3-B271-F6ADBE26C630Q54200853-50E59BC5-0C1C-450D-B011-65192660EFC5Q54203143-F6DADCE0-82F4-49C0-B703-FD32A5EE1DE7Q54957900-E751174D-057F-4411-91B5-935AEC50F432Q55047634-4B264CB3-F484-4399-8598-AA8D5DDE8658Q56781822-A6E8C0F5-7B37-43DC-A89A-1534A8ACD3B5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexis B Cortot
@ast
Alexis B Cortot
@en
Alexis B Cortot
@es
Alexis B Cortot
@nl
type
label
Alexis B Cortot
@ast
Alexis B Cortot
@en
Alexis B Cortot
@es
Alexis B Cortot
@nl
prefLabel
Alexis B Cortot
@ast
Alexis B Cortot
@en
Alexis B Cortot
@es
Alexis B Cortot
@nl
P106
P31
P496
0000-0003-0098-2238